Multiomics Research Strategies in Cancer: A Growing and Innovative Field

Abstract

Cancer is a highly complex and heterogeneous disease involving multiple pathophysiological events. Despite significant advances in modern medicine, the molecular mechanisms of cancer are still largely unknown. Omics methods have opened new avenues for identifying cancer biomarkers and elucidating disease pathogenesis. However, single-omics approaches only provide a limited understanding of biological mechanisms. The comprehensive analysis of multiomics data will provide useful insights for the pathogenesis, identification of therapeutic targets, and discovery of biomarkers in cancer. Here, we reviewed the disease signatures of cancer. We then reviewed the current state of multiomics biomarkers research in cancer. To further delineate the upstream pathogenic changes and downstream molecular effects of cancer, we also discuss the current strategies for integrating multiomics data using deep learning approaches. In addition, single-cell and spatial omics are being used to guide treatment strategies, risk assessment, and early diagnosis, as well as their potential impact on precision medicine. Despite the relative youth of the field, the development of single-cell and spatial omics promises to provide a powerful tool for elucidating the pathogenesis of cancer.

Keywords

biomarkers / cancer / deep learning / multiomics / precision medicine / single-cell omics / spatial omics

References

[1] A. Chakrabortty, D. J. Patton, B. F. Smith, et al., “miRNAs: Potential as Biomarkers and Therapeutic Targets for Cancer,” Genes (Basel) 14, no. 7 (2023): 1375.

[2] H. Beklen, E. Yildirim, M. Kori, et al., “Systems-level Biomarkers Identification and Drug Repositioning in Colorectal Cancer,” World Journal of Gastrointestinal Oncology 13 (2021): 638–661.

[3] V. Gonzalez-Covarrubias, E. Martínez-Martínez, and L. Del Bosque-Plata, “The Potential of Metabolomics in Biomedical Applications,” Metabolites 12 (2022).

[4] I. Ullah, L. Yang, F. T. Yin, et al., “Multi-Omics Approaches in Colorectal Cancer Screening and Diagnosis, Recent Updates and Future Perspectives,” Cancers (Basel) 14, no. 22 (2022): 5545.

[5] C. Donisi, A. Pretta, V. Pusceddu, et al., “Immunotherapy and Cancer: The Multi-Omics Perspective,” International Journal of Molecular Sciences 25 (2024): 3563.

[6] X. Qian, K. D. Harris, T. Hauling, et al., “Probabilistic Cell Typing Enables Fine Mapping of Closely Related Cell Types in Situ,” Nature Methods 17 (2020): 101–106.

[7] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71 (2021): 209–249.

[8] E. Morgan, M. Arnold, A. Gini, et al., “Global Burden of Colorectal Cancer in 2020 and 2040: Incidence and Mortality Estimates From GLOBOCAN,” Gut 72 (2023): 338–344.

[9] K. Satoh, L. Zhang, Y. Zhang, et al., “Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma,” Clinical Cancer Research 22 (2016): 3458–3466.

[10] M. Zhou, A. Varol, and T. Efferth, “Multi-omics Approaches to Improve Malaria Therapy,” Pharmacological Research 167 (2021): 105570.

[11] J. M. Zielinski, J. J. Luke, S. Guglietta, et al., “High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery,” Frontiers in Immunology 12 (2021): 590742.

[12] R. Ramanan, B. H. Kim, D. H. Cho, et al., “Algae-bacteria Interactions: Evolution, Ecology and Emerging Applications,” Biotechnology Advances 34 (2016): 14–29.

[13] K. Dudnyk, D. Cai, C. Shi, et al., “Sequence Basis of Transcription Initiation in the human Genome,” Science 384 (2024): eadj0116.

[14] F. Menghi and E. T. Liu, “Functional Genomics of Complex Cancer Genomes,” Nature Communications 13 (2022): 5908.

[15] B. E. Slatko, A. F. Gardner, and F. M. Ausubel, “Overview of Next-Generation Sequencing Technologies,” Current Protocols in Molecular Biology 122 (2018): e59.

[16] E. R. Mardis, “The Impact of next-generation Sequencing Technology on Genetics,” Trends in Genetics 24 (2008): 133–141.

[17] N. Navin, J. Kendall, J. Troge, et al., “Tumour Evolution Inferred by Single-cell Sequencing,” Nature 472 (2011): 90–94.

[18] A. Yasen, A. Aini, H. Wang, et al., “Progress and Applications of Single-cell Sequencing Techniques,” Infection, Genetics and Evolution 80 (2020): 104198.

[19] C. Gawad, W. Koh, and S. R. Quake, “Single-cell Genome Sequencing: Current state of the Science,” Nature Reviews Genetics 17 (2016): 175–188.

[20] I. C. Macaulay and T. Voet, “Single Cell Genomics: Advances and Future Perspectives,” PLOS Genetics 10 (2014): e1004126.

[21] P. Y. Kao, K. H. Leung, L. W. Chan, et al., “Pathway Analysis of Complex Diseases for GWAS, Extending to Consider Rare Variants, Multi-omics and Interactions,” Biochimica et Biophysica Acta (BBA) - General Subjects 1861 (2017): 335–353.

[22] R. Su, X. Wu, L. Tao, et al., “The Role of Epigenetic Modifications in Colorectal Cancer Metastasis,” Clinical & Experimental Metastasis 39 (2022): 521–539.

[23] M. E. Neganova, S. G. Klochkov, Y. R. Aleksandrova, et al., “Histone Modifications in Epigenetic Regulation of Cancer: Perspectives and Achieved Progress,” Seminars in Cancer Biology 83 (2022): 452–471.

[24] D. Dominissini, S. Moshitch-Moshkovitz, S. Schwartz, et al., “Topology of the human and Mouse m6A RNA Methylomes Revealed by m6A-seq,” Nature 485 (2012): 201–206.

[25] Z. Zhang, L. Q. Chen, Y. L. Zhao, et al., “Single-base Mapping of M(6)A by an Antibody-independent Method,” Science Advances 5 (2019): eaax0250.

[26] Y. Wang, Y. Xiao, S. Dong, et al., “Antibody-free Enzyme-assisted Chemical Approach for Detection of N(6)-methyladenosine,” Nature Chemical Biology 16 (2020): 896–903.

[27] H. Fan, F. Yang, Z. Xiao, et al., “Lactylation: Novel Epigenetic Regulatory and Therapeutic Opportunities,” American Journal of Physiology. Endocrinology and Metabolism 324 (2023): E330–E338.

[28] E. Gangoso, B. Southgate, L. Bradley, et al., “Glioblastomas Acquire Myeloid-affiliated Transcriptional Programs via Epigenetic Immunoediting to Elicit Immune Evasion,” Cell 184 (2021): 2454–2470. e26.

[29] F. Recillas-Targa, “Cancer Epigenetics: An Overview,” Archives of Medical Research 53 (2022): 732–740.

[30] S. A. Amundson, “Transcriptomics for Radiation Biodosimetry: Progress and Challenges,” International Journal of Radiation Biology 99 (2023): 925–933.

[31] T. C. Roberts, H. J. Johansson, G. McClorey, et al., “Multi-level Omics Analysis in a Murine Model of Dystrophin Loss and Therapeutic Restoration,” Human Molecular Genetics 24 (2015): 6756–6768.

[32] B. D. Aevermann, M. Novotny, T. Bakken, et al., “Cell Type Discovery Using Single-cell Transcriptomics: Implications for Ontological Representation,” Human Molecular Genetics 27 (2018): R40–R47.

[33] T. Peng, Q. Zhu, P. Yin, et al., “SCRABBLE: Single-cell RNA-seq Imputation Constrained by Bulk RNA-seq Data,” Genome Biology 20 (2019): 88.

[34] A. M. Streets, X. Zhang, C. Cao, et al., “Microfluidic Single-cell Whole-transcriptome Sequencing,” Proceedings of the National Academy of Sciences of the United States of America 111 (2014): 7048–7053.

[35] Y. Deng, A. Finck, and R. Fan, “Single-Cell Omics Analyses Enabled by Microchip Technologies,” Annual Review of Biomedical Engineering 21 (2019): 365–393.

[36] J. Cerneckis, G. L. Ming, H. Song, et al., “The Rise of Epitranscriptomics: Recent Developments and Future Directions,” Trends in Pharmacological Sciences 45 (2024): 24–38.

[37] S. Delaunay, M. Helm, and M. Frye, “RNA Modifications in Physiology and Disease: Towards Clinical Applications,” Nature Reviews Genetics 25 (2024): 104–122.

[38] M. Witzenberger and S. Schwartz, “Directing RNA-modifying Machineries towards Endogenous RNAs: Opportunities and Challenges,” Trends in Genetics 40 (2024): 313–325.

[39] E. Sendinc and Y. Shi, “RNA m6A Methylation Across the Transcriptome,” Molecular Cell 83 (2023): 428–441.

[40] K. Boulias and E. L. Greer, “Biological Roles of Adenine Methylation in RNA,” Nature Reviews Genetics 24 (2023): 143–160.

[41] A. L. Mattei, N. Bailly, and A. Meissner, “DNA Methylation: A Historical Perspective,” Trends in Genetics 38 (2022): 676–707.

[42] F. Mattiroli and L. Penengo, “Histone Ubiquitination: An Integrative Signaling Platform in Genome Stability,” Trends in Genetics 37 (2021): 566–581.

[43] W. P. Blackstock and M. P. Weir, “Proteomics: Quantitative and Physical Mapping of Cellular Proteins,” Trends in Biotechnology 17 (1999): 121–127.

[44] K. L. Bennett, M. Funk, M. Tschernutter, et al., “Proteomic Analysis of human Cataract Aqueous Humour: Comparison of One-dimensional Gel LCMS With Two-dimensional LCMS of Unlabelled and iTRAQ-labelled Specimens,” Journal of Proteomics 74 (2011): 151–166.

[45] S. Irar, F. Brini, K. Masmoudi, et al., “Combination of 2DE and LC for Plant Proteomics Analysis,” Methods in Molecular Biology 1072 (2014): 131–140.

[46] A. Stalmach, A. Albalat, W. Mullen, et al., “Recent Advances in Capillary Electrophoresis Coupled to Mass Spectrometry for Clinical Proteomic Applications,” Electrophoresis 34 (2013): 1452–1464.

[47] A. Venkatesh, S. K. Patel, S. Ray, et al., “Proteomics of Plasmodium Vivax Malaria: New Insights, Progress and Potential,” Expert Review of Proteomics 13 (2016): 771–782.

[48] R. L. E. Hugo and G. W. Birrell, “Proteomics of Anopheles Vectors of Malaria,” Trends in Parasitology 34 (2018): 961–981.

[49] C. Proietti, M. Zakrzewski, T. S. Watkins, et al., “Mining, Visualizing and Comparing Multidimensional Biomolecular Data Using the Genomics Data Miner (GMine) Web-Server,” Scientific Reports 6 (2016): 38178.

[50] Y. Zhang, W. Qin, and C. Wang, “Discovery of Post-translational Modifications in Immunometabolism by Chemical Proteomics,” Current Opinion in Biotechnology 68 (2021): 37–43.

[51] P. H. Lindhorst and A. B. Hummon, “Proteomics of Colorectal Cancer: Tumors, Organoids, and Cell Cultures-A Minireview,” Frontiers in Molecular Biosciences 7 (2020): 604492.

[52] J. K. Nicholson, J. C. Lindon, and E. Holmes, “Metabonomics': Understanding the Metabolic Responses of Living Systems to Pathophysiological Stimuli via Multivariate Statistical Analysis of Biological NMR Spectroscopic Data,” Xenobiotica 29 (1999): 1181–1189.

[53] L. Xiayan and C. Legido-Quigley, “Advances in Separation Science Applied to Metabonomics,” Electrophoresis 29 (2008): 3724–3736.

[54] J. Trygg, E. Holmes, and T. Lundstedt, “Chemometrics in Metabonomics,” Journal of Proteome Research 6 (2007): 469–479.

[55] R. Tautenhahn, G. J. Patti, D. Rinehart, et al., “XCMS Online: A Web-based Platform to Process Untargeted Metabolomic Data,” Analytical Chemistry 84 (2012): 5035–5039.

[56] M. Katajamaa, J. Miettinen, and M. Oresic, “MZmine: Toolbox for Processing and Visualization of Mass Spectrometry Based Molecular Profile Data,” Bioinformatics 22 (2006): 634–636.

[57] A. Lommen, “MetAlign: Interface-driven, Versatile Metabolomics Tool for Hyphenated Full-scan Mass Spectrometry Data Preprocessing,” Analytical Chemistry 81 (2009): 3079–3086.

[58] R. Baran, H. Kochi, N. Saito, et al., “MathDAMP: A Package for Differential Analysis of Metabolite Profiles,” BMC Bioinformatics [Electronic Resource] 7 (2006): 530.

[59] P. Bettenfeld, F. Fontaine, S. Trouvelot, et al., “Woody Plant Declines. What's Wrong With the Microbiome?,” Trends in Plant Science 25 (2020): 381–394.

[60] C. Wu, F. Zhou, J. Ren, et al., “A Selective Review of Multi-Level Omics Data Integration Using Variable Selection,” High Throughput 8 (2019): 4.

[61] F. Rohart, B. Gautier, A. Singh, et al., “mixOmics: An R Package for 'omics Feature Selection and Multiple Data Integration,” Plos Computational Biology 13 (2017): e1005752.

[62] M. Picard, M. P. Scott-Boyer, A. Bodein, et al., “Integration Strategies of Multi-omics Data for Machine Learning Analysis,” Computational and Structural Biotechnology Journal 19 (2021): 3735–3746.

[63] Z. Shahraki, A. Mohamadi, M. Rastkar, et al., “Male Factor Infertility and Risk of Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis,” Journal of Family and Reproductive Health 17 (2023): 194–198.

[64] G. Xie, C. Dong, Y. Kong, et al., “Group Lasso Regularized Deep Learning for Cancer Prognosis From Multi-Omics and Clinical Features,” Genes (Basel) 10 (2019): 240.

[65] K. Chaudhary, O. B. Poirion, L. Lu, et al., “Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer,” Clinical Cancer Research 24 (2018): 1248–1259.

[66] A. Talukder, C. Barham, X. Li, et al., “Interpretation of Deep Learning in Genomics and Epigenomics,” Briefings in Bioinformatics 22 (2021): bbaa177.

[67] M. Altenbuchinger, A. Weihs, J. Quackenbush, et al., “Gaussian and Mixed Graphical Models as (multi-)Omics Data Analysis Tools,” Biochimica et Biophysica Acta (BBA) – Gene Regulatory Mechanisms 1863 (2020): 194418.

[68] J. Zierer, T. Pallister, P. C. Tsai, et al., “Exploring the Molecular Basis of Age-related Disease Comorbidities Using a Multi-omics Graphical Model,” Scientific Reports 6 (2016): 37646.

[69] S. Zhang, C. C. Liu, W. Li, et al., “Discovery of Multi-dimensional Modules by Integrative Analysis of Cancer Genomic Data,” Nucleic Acids Research 40 (2012): 9379–9391.

[70] P. Chalise and B. L. Fridley, “Integrative Clustering of Multi-level 'omic Data Based on Non-negative Matrix Factorization Algorithm,” PLoS ONE 12 (2017): e0176278.

[71] D. Sun, M. Wang, and A. Li, “A Multimodal Deep Neural Network for Human Breast Cancer Prognosis Prediction by Integrating Multi-Dimensional Data,” IEEE/ACM Transactions on Computational Biology and Bioinformatics 16 (2019): 841–850.

[72] T. Wang, W. Shao, Z. Huang, et al., “MORONET: Multi-omics Integration via Graph Convolutional Networks for Biomedical Data Classification,” BioRxiv (2020).

[73] Q. Ma and D. Xu, “Deep Learning Shapes Single-cell Data Analysis,” Nature Reviews Molecular Cell Biology 23 (2022): 303–304.

[74] L. Yu, C. Liu, J. Y. H. Yang, et al., “Ensemble Deep Learning of Embeddings for Clustering Multimodal Single-cell Omics Data,” Bioinformatics 39 (2023): btad382.

[75] A. Marra, S. Morganti, F. Pareja, et al., “Artificial Intelligence Entering the Pathology Arena in Oncology: Current Applications and Future Perspectives,” Annals of Oncology 36 (2025): 712–725.

[76] E. Domingo, R. Ramamoorthy, D. Oukrif, et al., “Use of Multivariate Analysis to Suggest a New Molecular Classification of Colorectal Cancer,” Journal of Pathology 229 (2013): 441–448.

[77] Y. Liu, N. S. Sethi, T. Hinoue, et al., “Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas,” Cancer Cell 33 (2018): 721–735. e8.

[78] C. C. Simons, L. A. Hughes, K. M. Smits, et al., “A Novel Classification of Colorectal Tumors Based on Microsatellite Instability, the CpG Island Methylator Phenotype and Chromosomal Instability: Implications for Prognosis,” Annals of Oncology 24 (2013): 2048–2056.

[79] L. H. Nguyen, A. Goel, and D. C. Chung, “Pathways of Colorectal Carcinogenesis,” Gastroenterology 158 (2020): 291–302.

[80] K. L. Rudolph, M. Millard, M. W. Bosenberg, et al., “Telomere Dysfunction and Evolution of Intestinal Carcinoma in Mice and Humans,” Nature Genetics 28 (2001): 155–159.

[81] S. E. Artandi, S. Chang, S. L. Lee, et al., “Telomere Dysfunction Promotes Non-reciprocal Translocations and Epithelial Cancers in Mice,” Nature 406 (2000): 641–645.

[82] A. Sakthianandeswaren, M. J. Parsons, D. Mouradov, et al., “MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors,” Cancer Discovery 8 (2018): 988–1005.

[83] G. M. Li, “Mechanisms and Functions of DNA Mismatch Repair,” Cell Research 18 (2008): 85–98.

[84] M. V. Liberti and J. W. Locasale, “The Warburg Effect: How Does It Benefit Cancer Cells?,” Trends in Biochemical Sciences 41 (2016): 211–218.

[85] S. S. Tseng-Rogenski, Y. Hamaya, D. Y. Choi, et al., “Interleukin 6 Alters Localization of hMSH3, Leading to DNA Mismatch Repair Defects in Colorectal Cancer Cells,” Gastroenterology 148 (2015): 579–589.

[86] K. Søreide, M. M. Watson, and H. R. Hagland, “Deciphering the Molecular Code to Colorectal Liver Metastasis Biology through Microsatellite Alterations and Allelic Loss: The Good, the Bad, and the Ugly,” Gastroenterology 150 (2016): 811–814.

[87] T. de Lange, “Shelterin: The Protein Complex That Shapes and Safeguards human Telomeres,” Genes & Development 19 (2005): 2100–2110.

[88] J. O'Sullivan, R. A. Risques, M. T. Mandelson, et al., “Telomere Length in the Colon Declines With Age: A Relation to Colorectal Cancer?,” Cancer Epidemiology and Prevention Biomarkers 15 (2006): 573–577.

[89] R. A. Risques, L. A. Lai, T. A. Brentnall, et al., “Ulcerative Colitis Is a Disease of Accelerated Colon Aging: Evidence From Telomere Attrition and DNA Damage,” Gastroenterology 135 (2008): 410–418.

[90] J. A. Eaden, K. R. Abrams, and J. F. Mayberry, “The Risk of Colorectal Cancer in Ulcerative Colitis: A Meta-analysis,” Gut 48 (2001): 526–535.

[91] D. Chakravarti, B. Hu, X. Mao, et al., “Telomere Dysfunction Activates YAP1 to Drive Tissue Inflammation,” Nature Communications 11 (2020): 4766.

[92] D. Jurk, C. Wilson, J. F. Passos, et al., “Chronic Inflammation Induces Telomere Dysfunction and Accelerates Ageing in Mice,” Nature Communications 2 (2014): 4172.

[93] J. Nassour, R. Radford, A. Correia, et al., “Autophagic Cell Death Restricts Chromosomal Instability During Replicative Crisis,” Nature 565 (2019): 659–663.

[94] P. Cejas, E. Casado, C. Belda-Iniesta, et al., “Implications of Oxidative Stress and Cell Membrane Lipid Peroxidation in human Cancer (Spain),” Cancer Causes & Control 15 (2004): 707–719.

[95] L. J. Marnett, “Oxyradicals and DNA Damage,” Carcinogenesis 21 (2000): 361–370.

[96] T. Grune, K. Merker, G. Sandig, et al., “Selective Degradation of Oxidatively Modified Protein Substrates by the Proteasome,” Biochemical and Biophysical Research Communications 305 (2003): 709–718.

[97] R. Bertorelle, M. Briarava, E. Rampazzo, et al., “Telomerase Is an Independent Prognostic Marker of Overall Survival in Patients With Colorectal Cancer,” British Journal of Cancer 108 (2013): 278–284.

[98] A. K. Siraj, R. Bu, K. Iqbal, et al., “Telomerase Reverse Transcriptase Promoter Mutations in Cancers Derived From Multiple Organ Sites Among Middle Eastern Population,” Genomics 112 (2020): 1746–1753.

[99] T. D. Barber, B. Vogelstein, K. W. Kinzler, et al., “Somatic Mutations of EGFR in Colorectal Cancers and Glioblastomas,” New England Journal of Medicine 351 (2004): 2883.

[100] J. P. Spano, C. Lagorce, D. Atlan, et al., “Impact of EGFR Expression on Colorectal Cancer Patient Prognosis and Survival,” Annals of Oncology 16 (2005): 102–108.

[101] H. W. Liao, J. M. Hsu, W. Xia, et al., “PRMT1-mediated Methylation of the EGF Receptor Regulates Signaling and Cetuximab Response,” Journal of Clinical Investigation 125 (2015): 4529–4543.

[102] A. Woolston, K. Khan, G. Spain, et al., “Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution During Anti-EGFR Treatment in Colorectal Cancer,” Cancer Cell 36 (2019): 35–50. e9.

[103] S. P. J. Joosten, T. Mizutani, M. Spaargaren, et al., “MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance,” Gastroenterology 157 (2019): 1153–1155. e1.

[104] S. M. Kavuri, N. Jain, F. Galimi, et al., “HER2 activating Mutations Are Targets for Colorectal Cancer Treatment,” Cancer Discovery 5 (2015): 832–841.

[105] F. Di Nicolantonio, M. Martini, F. Molinari, et al., “Wild-type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer,” Journal of Clinical Oncology 26 (2008): 5705–5712.

[106] C. P. Vaughn, S. D. Zobell, L. V. Furtado, et al., “Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer,” Genes, Chromosomes & Cancer 50 (2011): 307–312.

[107] J. Canon, K. Rex, A. Y. Saiki, et al., “The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-tumour Immunity,” Nature 575 (2019): 217–223.

[108] D. S. Hong, M. G. Fakih, J. H. Strickler, et al., “KRAS(G12C) Inhibition With Sotorasib in Advanced Solid Tumors,” New England Journal of Medicine 383 (2020): 1207–1217.

[109] H. Davies, G. R. Bignell, C. Cox, et al., “Mutations of the BRAF Gene in human Cancer,” Nature 417 (2002): 949–954.

[110] W. De Roock, V. De Vriendt, and N. Normanno, “KRAS, BRAF, PIK3CA, and PTEN Mutations: Implications for Targeted Therapies in Metastatic Colorectal Cancer,” The Lancet Oncology 12 (2011): 594–603.

[111] E. Sanz-Garcia, G. Argiles, E. Elez, et al., “BRAF Mutant Colorectal Cancer: Prognosis, Treatment, and New Perspectives,” Annals of Oncology 28 (2017): 2648–2657.

[112] Y. Suh, F. Afaq, J. J. Johnson, et al., “A Plant Flavonoid Fisetin Induces Apoptosis in Colon Cancer Cells by Inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling Pathways,” Carcinogenesis 30 (2009): 300–307.

[113] R. B. Corcoran, H. Ebi, A. B. Turke, et al., “EGFR-mediated Re-activation of MAPK Signaling Contributes to Insensitivity of BRAF Mutant Colorectal Cancers to RAF Inhibition With Vemurafenib,” Cancer Discovery 2 (2012): 227–235.

[114] J. Luo, B. D. Manning, and L. C. Cantley, “Targeting the PI3K-Akt Pathway in human Cancer: Rationale and Promise,” Cancer Cell 4 (2003): 257–262.

[115] B. S. Jaiswal, V. Janakiraman, N. M. Kljavin, et al., “Somatic Mutations in p85alpha Promote Tumorigenesis Through Class IA PI3K Activation,” Cancer Cell 16 (2009): 463–474.

[116] K. M. Haigis, “KRAS Alleles: The Devil Is in the Detail,” Trends in Cancer 3 (2017): 686–697.

[117] S. Gupta, A. R. Ramjaun, P. Haiko, et al., “Binding of Ras to Phosphoinositide 3-kinase p110alpha Is Required for Ras-driven Tumorigenesis in Mice,” Cell 129 (2007): 957–968.

[118] D. C. Fingar, S. Salama, C. Tsou, et al., “Mammalian Cell Size Is Controlled by mTOR and Its Downstream Targets S6K1 and 4EBP1/eIF4E,” Genes & Development 16 (2002): 1472–1487.

[119] T. M. Foley, S. N. Payne, C. A. Pasch, et al., “Dual PI3K/mTOR Inhibition in Colorectal Cancers With APC and PIK3CA Mutations,” Molecular Cancer Research 15 (2017): 317–327.

[120] K. Hoffmeyer, A. Raggioli, S. Rudloff, et al., “Wnt/β-catenin Signaling Regulates Telomerase in Stem Cells and Cancer Cells,” Science 336 (2012): 1549–1554.

[121] L. E. Dow, K. P. O'Rourke, J. Simon, et al., “Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer,” Cell 161 (2015): 1539–1552.

[122] Y. S. Jung, S. Jun, M. J. Kim, et al., “TMEM9 promotes Intestinal Tumorigenesis Through Vacuolar-ATPase-activated Wnt/β-catenin Signalling,” Nature Cell Biology 20 (2018): 1421–1433.

[123] J. Zhang, H. Tsoi, X. Li, et al., “Carbonic Anhydrase IV Inhibits Colon Cancer Development by Inhibiting the Wnt Signalling Pathway Through Targeting the WTAP-WT1-TBL1 Axis,” Gut 65 (2016): 1482–1493.

[124] H. Yuan, N. Li, D. Fu, et al., “Histone Methyltransferase SETD2 Modulates Alternative Splicing to Inhibit Intestinal Tumorigenesis,” Journal of Clinical Investigation 127 (2017): 3375–3391.

[125] F. Hua, S. Shang, Y. W. Yang, et al., “TRIB3 Interacts with β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis,” Gastroenterology 156 (2019): 708–721. e15.

[126] K. Peng, L. Kou, L. Yu, et al., “Histone Demethylase JMJD2D Interacts with β-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice,” Gastroenterology 156 (2019): 1112–1126.

[127] B. T. MacDonald, K. Tamai, and X. He, “Wnt/Beta-catenin Signaling: Components, Mechanisms, and Diseases,” Developmental Cell 17 (2009): 9–26.

[128] H. Clevers and R. Nusse, “Wnt/β-catenin Signaling and Disease,” Cell 149 (2012): 1192–1205.

[129] L. Novellasdemunt, A. Kucharska, C. Jamieson, et al., “NEDD4 and NEDD4L Regulate Wnt Signalling and Intestinal Stem Cell Priming by Degrading LGR5 Receptor,” Embo Journal 39 (2020): e102771.

[130] S. O. Kleeman, V. H. Koelzer, H. J. Jones, et al., “Exploiting Differential Wnt Target Gene Expression to Generate a Molecular Biomarker for Colorectal Cancer Stratification,” Gut 69 (2020): 1092–1103.

[131] M. Housini, B. Dariya, N. Ahmed, et al., “Colorectal Cancer: Genetic Alterations, Novel Biomarkers, Current Therapeutic Strategies and Clinical Trials,” Gene 892 (2024): 147857.

[132] B. Jagadeesan, P. Gerner-Smidt, M. W. Allard, et al., “The Use of next Generation Sequencing for Improving Food Safety: Translation Into Practice,” Food Microbiology 79 (2019): 96–115.

[133] S. Ghatak, S. F. Mehrabi, L. M. Mehdawi, et al., “Identification of a Novel Five-Gene Signature as a Prognostic and Diagnostic Biomarker in Colorectal Cancers,” International Journal of Molecular Sciences 23 (2022): 793.

[134] H. Y. S. Essa, G. Kusaf, O. Yuruker, et al., “Epigenetic Alteration in Colorectal Cancer: A Biomarker for Diagnostic and Therapeutic Application,” Global Medical Genetics 9 (2022): 258–262.

[135] S. C. H. Chan and J. Q. Liang, “Advances in Tests for Colorectal Cancer Screening and Diagnosis,” Expert Review of Molecular Diagnostics 22 (2022): 449–460.

[136] H. Postwala, Y. Shah, P. S. Parekh, et al., “Unveiling the Genetic and Epigenetic Landscape of Colorectal Cancer: New Insights Into Pathogenic Pathways,” Medical Oncology 40 (2023): 334.

[137] D. Müller and B. Győrffy, “DNA Methylation-based Diagnostic, Prognostic, and Predictive Biomarkers in Colorectal Cancer,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877 (2022): 188722.

[138] F. Sarno, G. Benincasa, M. List, et al., “Clinical Epigenetics Settings for Cancer and Cardiovascular Diseases: Real-life Applications of Network Medicine at the Bedside,” Clinical Epigenetics 13 (2021): 66.

[139] M. Berdasco and M. Esteller, “Clinical Epigenetics: Seizing Opportunities for Translation,” Nature Reviews Genetics 20 (2019): 109–127.

[140] Y. Lin, Z. Zhao, W. Nie, et al., “Overview of Distinct 5-methylcytosine Profiles of Messenger RNA in Normal and Knock-Down NSUN2 Colorectal Cancer Cells,” Frontiers in Genetics 14 (2023): 1121063.

[141] S. Chen, X. Cao, S. Ben, et al., “Genetic Variants in RNA M(5) C Modification Genes Associated With Survival and Chemotherapy Efficacy of Colorectal Cancer,” Cancer Medicine 12 (2023): 1376–1388.

[142] X. Fang, C. Miao, T. Zeng, et al., “Role of M(5) C RNA Methylation Regulators in Colorectal Cancer Prognosis and Immune Microenvironment,” Journal of Clinical Laboratory Analysis 36 (2022): e24303.

[143] Z. Xiao, W. Wu, C. Wu, et al., “5-Hydroxymethylcytosine Signature in Circulating Cell-free DNA as a Potential Diagnostic Factor for Early-stage Colorectal Cancer and Precancerous Adenoma,” Molecular Oncology 15 (2021): 138–150.

[144] H. Yin, Z. Huang, S. Niu, et al., “5-Methylcytosine (m(5)C) Modification in Peripheral Blood Immune Cells Is a Novel Non-invasive Biomarker for Colorectal Cancer Diagnosis,” Frontiers in Immunology 13 (2022): 967921.

[145] P. Zhang, T. Zhang, D. Chen, et al., “Prognosis and Novel Drug Targets for Key lncRNAs of Epigenetic Modification in Colorectal Cancer,” Mediators of Inflammation 2023 (2023): 6632205.

[146] X. Song, T. Tang, C. Li, et al., “CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer,” Medical Science Monitor 24 (2018): 7820–7827.

[147] K. Moradi, E. Babaei, M. A. Hosseinpour Feizi, et al., “Quantitative Detection of SRY-Box 21 (SOX21) Gene Promoter Methylation as a Stool-based Noninvasive Biomarker for Early Diagnosis of Colorectal Cancer by MethyLight Method,” Indian Journal of Cancer 58 (2021): 217–224.

[148] L. Y. Cheng, M. S. Huang, H. G. Zhong, et al., “MTUS1 is a Promising Diagnostic and Prognostic Biomarker for Colorectal Cancer,” World Journal of Surgical Oncology 20 (2022): 257.

[149] S. Gu, S. Qian, S. Lin, et al., “Promoter Hypermethylation of GALR1 Acts as an Early Epigenetic Susceptibility Event in Colorectal Carcinogenesis,” Journal of Human Genetics 67 (2022): 519–525.

[150] L. Shen, W. Lu, Y. Huang, et al., “SNORD15B and SNORA5C: Novel Diagnostic and Prognostic Biomarkers for Colorectal Cancer,” BioMed Research International 2022 (2022): 8260800.

[151] Y. J. Wang, M. Liu, H. Y. Jiang, et al., “Downregulation of LRRC19 Is Associated With Poor Prognosis in Colorectal Cancer,” Journal of Oncology 2022 (2022): 5848823.

[152] T. Nojima and N. J. Proudfoot, “Mechanisms of lncRNA Biogenesis as Revealed by Nascent Transcriptomics,” Nature Reviews Molecular Cell Biology 23 (2022): 389–406.

[153] M. Maleki, A. Golchin, S. Javadi, et al., “Role of Exosomal miRNA in Chemotherapy Resistance of Colorectal Cancer: A Systematic Review,” Chemical Biology & Drug Design (2021).

[154] L. Wang and L. Zhang, “MicroRNAs in Amyotrophic Lateral Sclerosis: From Pathogenetic Involvement to Diagnostic Biomarker and Therapeutic Agent Development,” Neurological Sciences 41 (2020).

[155] S. Blondy, V. David, M. Verdier, et al., “5-Fluorouracil Resistance Mechanisms in Colorectal Cancer: From Classical Pathways to Promising Processes,” Cancer Science 111 (2020): 3142–3154.

[156] B. Pardini, G. Ferrero, S. Tarallo, et al., “A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results from a Multicenter Study,” Gastroenterology 165 (2023): 582–599. e8.

[157] K. Wai Hon, S. A. Zainal Abidin, I. Othman, et al., “Insights Into the Role of microRNAs in Colorectal Cancer (CRC) Metabolism,” Cancers (Basel) 12 (2020): 2462.

[158] B. Durán-Vinet, K. Araya-Castro, J. Calderón, et al., “CRISPR/Cas13-Based Platforms for a Potential Next-Generation Diagnosis of Colorectal Cancer Through Exosomes Micro-RNA Detection: A Review,” Cancers (Basel) 13 (2021): 4640.

[159] M. Gallardo-Gómez, L. De Chiara, P. Álvarez-Chaver, et al., “Colorectal Cancer Screening and Diagnosis: Omics-based Technologies for Development of a Non-invasive Blood-based Method,” Expert Review of Anticancer Therapy 21 (2021): 723–738.

[160] Y. Kashima, Y. Sakamoto, K. Kaneko, et al., “Single-cell Sequencing Techniques From Individual to Multiomics Analyses,” Experimental & Molecular Medicine 52 (2020): 1419–1427.

[161] J. Lee, D. Y. Hyeon, and D. Hwang, “Single-cell Multiomics: Technologies and Data Analysis Methods,” Experimental & Molecular Medicine 52 (2020): 1428–1442.

[162] K. Pelka, M. Hofree, J. H. Chen, et al., “Spatially Organized Multicellular Immune Hubs in human Colorectal Cancer,” Cell 184 (2021): 4734–4752. e20.

[163] Y. Chang, Z. Huang, F. Hou, et al., “Parvimonas micra Activates the Ras/ERK/c-Fos Pathway by Upregulating miR-218-5p to Promote Colorectal Cancer Progression,” Journal of Experimental & Clinical Cancer Research 42 (2023): 13.

[164] Y. Chen, S. Liu, S. Tan, et al., “KRAS Mutations Promote the Intratumoral Colonization of Enterotoxigenic bacteroides fragilis in Colorectal Cancer Through the Regulation of the miRNA3655/SURF6/IRF7/IFNβ Axis,” Gut Microbes 16 (2024): 2423043.

[165] Y. Sun, J. Lu, E. Y. Tung Lau, et al., “Fusobacterium nucleatum Enhances Cholesterol Biosynthesis in Colorectal Cancer via miR-130a-3p-mediated AMPK Inhibition, a Process Counteracted by Butyrate,” Cancer Letters 627 (2025): 217810.

[166] Y. Yu, H. Yin, B. Wu, et al., “Fusobacterium nucleatum Promotes Colorectal Cancer Liver Metastasis via miR-5692a/IL-8 Axis by Inducing Epithelial-mesenchymal Transition,” Journal of Biomedical Science 32 (2025): 5.

[167] Y. Ren, Y. Li, W. Zhang, et al., “Mir-4746 Inhibits the Proliferation of Colorectal Cancer Cells in Vitro and in Vivo by Targeting CCND1,” Biochemical and Biophysical Research Communications 594 (2022): 153–160.

[168] C. Wang, W. Liu, S. Yang, et al., “BAP31 Promotes Epithelial-Mesenchymal Transition Progression through the Exosomal miR-423-3p/Bim Axis in Colorectal Cancer,” International Journal of Molecular Sciences 26 (2025): 5483.

[169] E. Chen, Q. Li, H. Wang, et al., “MiR-92a Promotes Tumorigenesis of Colorectal Cancer, a Transcriptomic and Functional Based Study,” Biomedicine & Pharmacotherapy 106 (2018): 1370–1377.

[170] Y. Sun, S. Shen, H. Tang, et al., “miR-429 Identified by Dynamic Transcriptome Analysis Is a New Candidate Biomarker for Colorectal Cancer Prognosis,” Omics 18 (2014): 54–64.

[171] O. Fiala, P. Pitule, P. Hosek, et al., “The Association of miR-126-3p, miR-126-5p and miR-664-3p Expression Profiles With Outcomes of Patients With Metastatic Colorectal Cancer Treated With bevacizumab,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 39 (2017): 1010428317709283.

[172] N. Wang and W. Liu, “Increased Expression of miR-552 Acts as a Potential Predictor Biomarker for Poor Prognosis of Colorectal Cancer,” European Review for Medical and Pharmacological Sciences 22 (2018): 412–416.

[173] X. Liu, X. Xu, B. Pan, et al., “Circulating miR-1290 and miR-320d as Novel Diagnostic Biomarkers of Human Colorectal Cancer,” Journal of Cancer 10 (2019): 43–50.

[174] S. Zanutto, C. M. Ciniselli, A. Belfiore, et al., “Plasma miRNA-based Signatures in CRC Screening Programs,” International Journal of Cancer 146 (2020): 1164–1173.

[175] X. Cui, Z. Lv, H. Ding, et al., “MiR-1539 and Its Potential Role as a Novel Biomarker for Colorectal Cancer,” Frontiers in Oncology 10 (2020): 531244.

[176] D. Fu, Y. Chen, and D. Xu, “Circulating miR-449a Predicts Survival Outcome for Colorectal Cancer Following Curative Resection: An Observational Study,” Medicine 100 (2021): e25022.

[177] E. Kang, S. C. Jung, S. K. Nam, et al., “Tissue miR-200c-3p and Circulating miR-1290 as Potential Prognostic Biomarkers for Colorectal Cancer,” Scientific Reports 12 (2022): 2295.

[178] S. Saleh, A. Staes, S. Deborggraeve, et al., “Targeted Proteomics for Studying Pathogenic Bacteria,” Proteomics 19 (2019): e1800435.

[179] A. F. Schmidt, C. Finan, M. Gordillo-Marañón, et al., “Genetic Drug Target Validation Using Mendelian Randomisation,” Nature Communications 11 (2020): 3255.

[180] J. J. Hao, X. Zhi, Y. Wang, et al., “Comprehensive Proteomic Characterization of the Human Colorectal Carcinoma Reveals Signature Proteins and Perturbed Pathways,” Scientific Reports 7 (2017): 42436.

[181] S. Torres, R. A. Bartolomé, M. Mendes, et al., “Proteome Profiling of Cancer-associated Fibroblasts Identifies Novel Proinflammatory Signatures and Prognostic Markers for Colorectal Cancer,” Clinical Cancer Research 19 (2013): 6006–6019.

[182] A. Alnabulsi and G. I. Murray, “Proteomics for Early Detection of Colorectal Cancer: Recent Updates,” Expert Review of Proteomics 15 (2018): 55–63.

[183] M. Bhardwaj, A. Gies, K. Weigl, et al., “Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer,” Cancers (Basel) 11 (2019): 1426.

[184] J. Chantaraamporn, V. Champattanachai, A. Khongmanee, et al., “Glycoproteomic Analysis Reveals Aberrant Expression of Complement C9 and Fibronectin in the Plasma of Patients With Colorectal Cancer,” Proteomes 8 (2020): 26.

[185] J. Choo, G. Heo, C. Pothoulakis, et al., “Posttranslational Modifications as Therapeutic Targets for Intestinal Disorders,” Pharmacological Research 165 (2021): 105412.

[186] S. Aggarwal, P. Tolani, S. Gupta, et al., “Posttranslational Modifications in Systems Biology,” Advances in Protein Chemistry and Structural Biology 127 (2021): 93–126.

[187] A. V. Hartley, B. Wang, G. Jiang, et al., “Regulation of a PRMT5/NF-κB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer,” International Journal of Molecular Sciences 21 (2020): 3684.

[188] H. Jiang, L. Wu, J. Chen, et al., “Sulfiredoxin Promotes Colorectal Cancer Cell Invasion and Metastasis Through a Novel Mechanism of Enhancing EGFR Signaling,” Molecular Cancer Research 13 (2015): 1554–1566.

[189] H. Xu, Y. Wang, S. Lin, et al., “PTMD: A Database of Human Disease-associated Post-translational Modifications,” Genomics, Proteomics & Bioinformatics 16 (2018): 244–251.

[190] M. Hu, Y. Xu, Y. Wang, et al., “Gut Microbial-derived N-acetylmuramic Acid Alleviates Colorectal Cancer via the AKT1 Pathway,” Gut 74 (2025): 1230–1245.

[191] L. He, Z. Guo, W. Wang, et al., “FUT2 inhibits the EMT and Metastasis of Colorectal Cancer by Increasing LRP1 Fucosylation,” Cell Communication and Signaling 21 (2023): 63.

[192] Z. Ma, Y. Sun, Y. Yu, et al., “Extracellular Vesicles Containing MFGE8 From Colorectal Cancer Facilitate Macrophage Efferocytosis,” Cell Communication and Signaling 22 (2024): 295.

[193] S. Li, J. Zhang, S. Qian, et al., “S100A8 promotes Epithelial-mesenchymal Transition and Metastasis Under TGF-β/USF2 Axis in Colorectal Cancer,” Cancer Communications (London) 41 (2021): 154–170.

[194] Q. Gao, L. Yang, S. Ye, et al., “Targeting SIRT2 Induces MLH1 Deficiency and Boosts Antitumor Immunity in Preclinical Colorectal Cancer Models,” Science Translational Medicine 17 (2025): eadv0766.

[195] L. Huang, M. Wei, H. Li, et al., “GP73-dependent Regulation of Exosome Biogenesis Promotes Colorectal Cancer Liver Metastasis,” Molecular Cancer 24 (2025): 151.

[196] P. Martin, S. Noonan, M. P. Mullen, et al., “Predicting Response to Vascular Endothelial Growth Factor Inhibitor and Chemotherapy in Metastatic Colorectal Cancer,” BMC Cancer 14 (2014): 887.

[197] N. J. Fan, H. M. Chen, W. Song, et al., “Macrophage Mannose Receptor 1 and S100A9 Were Identified as Serum Diagnostic Biomarkers for Colorectal Cancer Through a Label-free Quantitative Proteomic Analysis,” Cancer Biomarkers 16 (2016): 235–243.

[198] S. Ghazanfar, I. Fatima, M. Aslam, et al., “Identification of Actin Beta-Like 2 (ACTBL2) as Novel, Upregulated Protein in Colorectal Cancer,” Journal of Proteomics 152 (2017): 33–40.

[199] J. Yu, X. Zhai, X. Li, et al., “Identification of MST1 as a Potential Early Detection Biomarker for Colorectal Cancer Through a Proteomic Approach,” Scientific Reports 7 (2017): 14265.

[200] K. Mori, Y. Toiyama, K. Otake, et al., “Proteomics Analysis of Differential Protein Expression Identifies Heat Shock Protein 47 as a Predictive Marker for Lymph Node Metastasis in Patients With Colorectal Cancer,” International Journal of Cancer 140 (2017): 1425–1435.

[201] M. Zajkowska, M. Dulewicz, A. Kulczyńska-Przybik, et al., “The Significance of Selected C-C Motif Chemokine Ligands in Colorectal Cancer Patients,” Journal of Clinical Medicine 11 (2022): 1794.

[202] Y. Sun, Z. Guo, X. Liu, et al., “Noninvasive Urinary Protein Signatures Associated With Colorectal Cancer Diagnosis and Metastasis,” Nature Communications 13 (2022): 2757.

[203] L. Mattoli, M. Gianni, and M. Burico, “Mass Spectrometry-based Metabolomic Analysis as a Tool for Quality Control of Natural Complex Products,” Mass Spectrometry Reviews 42 (2023): 1358–1396.

[204] J. Troisi, P. Cavallo, A. Colucci, et al., “Metabolomics in Genetic Testing,” Advances in Clinical Chemistry 94 (2020): 85–153.

[205] J. Ivanisevic and E. J. Want, “From Samples to Insights Into Metabolism: Uncovering Biologically Relevant Information in LC-HRMS Metabolomics Data,” Metabolites 9 (2019): 308.

[206] G. Nannini, G. Meoni, A. Amedei, et al., “Metabolomics Profile in Gastrointestinal Cancers: Update and Future Perspectives,” World Journal of Gastroenterology 26 (2020): 2514–2532.

[207] W. Ning, N. Qiao, X. Zhang, et al., “Metabolic Profiling Analysis for Clinical Urine of Colorectal Cancer,” Asia-Pacific Journal of Clinical Oncology 17 (2021): 403–413.

[208] E. M. Song, J. S. Byeon, S. M. Lee, et al., “Fecal Fatty Acid Profiling as a Potential New Screening Biomarker in Patients With Colorectal Cancer,” Digestive Diseases and Sciences 63 (2018): 1229–1236.

[209] Y. Lin, C. Ma, T. Bezabeh, et al., “(1) H NMR-based Metabolomics Reveal Overlapping Discriminatory Metabolites and Metabolic Pathway Disturbances Between Colorectal Tumor Tissues and Fecal Samples,” International Journal of Cancer 145 (2019): 1679–1689.

[210] M. Clos-Garcia, K. Garcia, C. Alonso, et al., “Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer,” Cancers (Basel) 12 (2020): 1142.

[211] F. T. Yin, X. H. Zhou, S. Y. Kang, et al., “Prediction of the Mechanism of Dachengqi Decoction Treating Colorectal Cancer Based on the Analysis Method of Into Serum Components -action Target-key Pathway,” Journal of Ethnopharmacology 293 (2022): 115286.

[212] Y. Sun, X. Zhang, D. Hang, et al., “Integrative Plasma and Fecal Metabolomics Identify Functional Metabolites in Adenoma-colorectal Cancer Progression and as Early Diagnostic Biomarkers,” Cancer Cell 42 (2024): 1386–1400. e8.

[213] X. Kang, C. Liu, Y. Ding, et al., “Roseburia Intestinalis Generated Butyrate Boosts Anti-PD-1 Efficacy in Colorectal Cancer by Activating Cytotoxic CD8(+) T Cells,” Gut 72 (2023): 2112–2122.

[214] J. Yang, H. Wei, Y. Zhou, et al., “High-Fat Diet Promotes Colorectal Tumorigenesis through Modulating Gut Microbiota and Metabolites,” Gastroenterology 162 (2022): 135–149. e2.

[215] X. Bai, Z. Duan, J. Deng, et al., “Ginsenoside Rh4 Inhibits Colorectal Cancer via the Modulation of Gut Microbiota-mediated Bile Acid Metabolism,” Journal of Advanced Research 72 (2025): 37–52.

[216] Q. Song, Y. Gao, K. Liu, et al., “Gut Microbial and Metabolomics Profiles Reveal the Potential Mechanism of Fecal Microbiota Transplantation in Modulating the Progression of Colitis-associated Colorectal Cancer in Mice,” Journal of Translational Medicine 22 (2024): 1028.

[217] K. Cai, X. Y. Cao, F. Chen, et al., “Xianlian Jiedu Decoction Alleviates Colorectal Cancer by Regulating Metabolic Profiles, Intestinal Microbiota and Metabolites,” Phytomedicine 128 (2024): 155385.

[218] S. Nishiumi, T. Kobayashi, A. Ikeda, et al., “A Novel Serum Metabolomics-based Diagnostic Approach for Colorectal Cancer,” PLoS ONE 7 (2012): e40459.

[219] A. J. Cross, S. C. Moore, S. Boca, et al., “A Prospective Study of Serum Metabolites and Colorectal Cancer Risk,” Cancer 120 (2014): 3049–3057.

[220] S. Nishiumi, T. Kobayashi, S. Kawana, et al., “Investigations in the Possibility of Early Detection of Colorectal Cancer by Gas Chromatography/Triple-quadrupole Mass Spectrometry,” Oncotarget 8 (2017): 17115–17126.

[221] E. R. Kim, H. N. Kwon, H. Nam, et al., “Urine-NMR Metabolomics for Screening of Advanced Colorectal Adenoma and Early Stage Colorectal Cancer,” Scientific Reports 9 (2019): 4786.

[222] J. Troisi, M. Tafuro, M. Lombardi, et al., “A Metabolomics-Based Screening Proposal for Colorectal Cancer,” Metabolites 12 (2022): 110.

[223] Z. Luo, H. Wang, S. Lin, et al., “Study on the Levels of N-nitrosamine Compounds and Untargeted Metabolomics in Patients With Colorectal Cancer,” Analytical and Bioanalytical Chemistry 414 (2022): 3483–3496.

[224] C. Kong, L. Liang, G. Liu, et al., “Integrated Metagenomic and Metabolomic Analysis Reveals Distinct Gut-microbiome-derived Phenotypes in Early-onset Colorectal Cancer,” Gut 72 (2023): 1129–1142.

[225] C. C. Wong and J. Yu, “Gut Microbiota in Colorectal Cancer Development and Therapy,” Nature Reviews Clinical Oncology 20 (2023): 429–452.

[226] T. F. S. Bastiaanssen, S. Cussotto, M. J. Claesson, et al., “Gutted! Unraveling the Role of the Microbiome in Major Depressive Disorder,” Harvard Review of Psychiatry 28 (2020): 26–39.

[227] J. Yang, D. Li, Z. Yang, et al., “Establishing High-accuracy Biomarkers for Colorectal Cancer by Comparing Fecal Microbiomes in Patients With Healthy Families,” Gut Microbes 11 (2020): 918–929.

[228] Y. Liu, H. C. Lau, W. Y. Cheng, et al., “Gut Microbiome in Colorectal Cancer: Clinical Diagnosis and Treatment,” Genomics, Proteomics & Bioinformatics 21 (2023): 84–96.

[229] G. D. Poore, E. Kopylova, Q. Zhu, et al., “Microbiome Analyses of Blood and Tissues Suggest Cancer Diagnostic Approach,” Nature 579 (2020): 567–574.

[230] J. Li, A. H. Zhang, F. F. Wu, et al., “Alterations in the Gut Microbiota and Their Metabolites in Colorectal Cancer: Recent Progress and Future Prospects,” Frontiers in Oncology 12 (2022): 841552.

[231] F. Chen, X. Dai, C. C. Zhou, et al., “Integrated Analysis of the Faecal Metagenome and Serum Metabolome Reveals the Role of Gut Microbiome-associated Metabolites in the Detection of Colorectal Cancer and Adenoma,” Gut 71 (2022): 1315–1325.

[232] D. G. Brown, S. Rao, T. L. Weir, et al., “Metabolomics and Metabolic Pathway Networks From human Colorectal Cancers, Adjacent Mucosa, and Stool,” Cancer & Metabolism 4 (2016): 11.

[233] Y. Yang, B. B. Misra, L. Liang, et al., “Integrated Microbiome and Metabolome Analysis Reveals a Novel Interplay Between Commensal Bacteria and Metabolites in Colorectal Cancer,” Theranostics 9 (2019): 4101–4114.

[234] S. Guo, L. Li, B. Xu, et al., “A Simple and Novel Fecal Biomarker for Colorectal Cancer: Ratio of Fusobacterium Nucleatum to Probiotics Populations, Based on Their Antagonistic Effect,” Clinical Chemistry 64 (2018): 1327–1337.

[235] H. Gou, H. Su, D. Liu, et al., “Traditional Medicine Pien Tze Huang Suppresses Colorectal Tumorigenesis through Restoring Gut Microbiota and Metabolites,” Gastroenterology 165 (2023): 1404–1419.

[236] Q. Liang, J. Chiu, Y. Chen, et al., “Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer,” Clinical Cancer Research 23 (2017): 2061–2070.

[237] J. Li, R. Chu, C. Wang, et al., “Microbiome Characteristics and Bifidobacterium Longum in Colorectal Cancer Patients Pre- and Post-chemotherapy,” Translational Cancer Research 9 (2020): 2178–2190.

[238] K. Liu, X. Yang, M. Zeng, et al., “The Role of Fecal Fusobacterium nucleatum and Pks(+) Escherichia coli as Early Diagnostic Markers of Colorectal Cancer,” Disease Markers 2021 (2021): 1171239.

[239] Y. Wang, Y. Zhang, Z. Wang, et al., “A Clinical Nomogram Incorporating Salivary Desulfovibrio Desulfuricans Level and Oral Hygiene Index for Predicting Colorectal Cancer,” Annals of Translational Medicine 9 (2021): 754.

[240] M. A. Osman, H. M. Neoh, N. S. Ab Mutalib, et al., “Parvimonas Micra, Peptostreptococcus Stomatis, Fusobacterium nucleatum and Akkermansia Muciniphila as a Four-bacteria Biomarker Panel of Colorectal Cancer,” Scientific Reports 11 (2021): 2925.

[241] N. N. Liu, N. Jiao, J. C. Tan, et al., “Multi-kingdom Microbiota Analyses Identify Bacterial-fungal Interactions and Biomarkers of Colorectal Cancer Across Cohorts,” Nature Microbiology 7 (2022): 238–250.

[242] Y. Lin, H. C. Lau, Y. Liu, et al., “Altered Mycobiota Signatures and Enriched Pathogenic Aspergillus Rambellii Are Associated with Colorectal Cancer Based on Multicohort Fecal Metagenomic Analyses,” Gastroenterology 163 (2022): 908–921.

[243] N. Zafari, P. Bathaei, M. Velayati, et al., “Integrated Analysis of Multi-omics Data for the Discovery of Biomarkers and Therapeutic Targets for Colorectal Cancer,” Computers in Biology and Medicine 155 (2023): 106639.

[244] A. J. Wang, D. Song, Y. M. Hong, et al., “Multi-omics Insights Into the Interplay Between Gut Microbiota and Colorectal Cancer in the, “Microworld” Age,” Molecular Omics 19 (2023): 283–296.

[245] G. Yang, X. R. Yu, D. J. Weisenberger, et al., “A Multi-Omics Overview of Colorectal Cancer to Address Mechanisms of Disease, Metastasis, Patient Disparities and Outcomes,” Cancers (Basel) 15 (2023): 2934.

[246] N. Dalal, R. Jalandra, M. Sharma, et al., “Omics Technologies for Improved Diagnosis and Treatment of Colorectal Cancer: Technical Advancement and Major Perspectives,” Biomedicine & Pharmacotherapy 131 (2020): 110648.

[247] Y. Peng, Y. Nie, J. Yu, et al., “Microbial Metabolites in Colorectal Cancer: Basic and Clinical Implications,” Metabolites 11 (2021): 159.

[248] T. L. Weir, D. K. Manter, A. M. Sheflin, et al., “Stool Microbiome and Metabolome Differences Between Colorectal Cancer Patients and Healthy Adults,” PLoS ONE 8 (2013): e70803.

[249] M. F. Loke, E. G. Chua, H. M. Gan, et al., “Metabolomics and 16S rRNA Sequencing of human Colorectal Cancers and Adjacent Mucosa,” PLoS ONE 13 (2018): e0208584.

[250] M. A. Sze, B. D. Topçuoğlu, N. A. Lesniak, et al., “Fecal Short-Chain Fatty Acids Are Not Predictive of Colonic Tumor Status and CanNot Be Predicted Based on Bacterial Community Structure,” MBio 10 (2019). e01454-19.

[251] G. Zhu, L. Pei, H. Xia, et al., “Role of Oncogenic KRAS in the Prognosis, Diagnosis and Treatment of Colorectal Cancer,” Molecular Cancer 20 (2021): 143.

[252] E. S. Gruber, G. Oberhuber, D. Pils, et al., “The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray,” Cancers (Basel) 12 (2020): 563.

[253] T. André, J. Meyerhardt, T. Iveson, et al., “Effect of Duration of Adjuvant Chemotherapy for Patients With Stage III Colon Cancer (IDEA collaboration): Final Results From a Prospective, Pooled Analysis of Six Randomised, Phase 3 Trials,” The Lancet Oncology 21 (2020): 1620–1629.

[254] A. Grothey, A. F. Sobrero, A. F. Shields, et al., “Duration of Adjuvant Chemotherapy for Stage III Colon Cancer,” New England Journal of Medicine 378 (2018): 1177–1188.

[255] S. Yachida, S. Mizutani, H. Shiroma, et al., “Metagenomic and Metabolomic Analyses Reveal Distinct Stage-specific Phenotypes of the Gut Microbiota in Colorectal Cancer,” Nature Medicine 25 (2019): 968–976.

[256] X. Guo, R. Wang, R. Chen, et al., “Gut Microbiota and Serum Metabolite Signatures Along the Colorectal Adenoma-carcinoma Sequence: Implications for Early Detection and Intervention,” Clinica Chimica Acta 560 (2024): 119732.

[257] Y. C. Yu, P. Paragomi, R. Wang, et al., “Composite Dietary Antioxidant Index and the Risk of Colorectal Cancer: Findings From the Singapore Chinese Health Study,” International Journal of Cancer 150 (2022): 1599–1608.

[258] H. M. Chen, Y. N. Yu, J. L. Wang, et al., “Decreased Dietary fiber Intake and Structural Alteration of Gut Microbiota in Patients With Advanced Colorectal Adenoma,” American Journal of Clinical Nutrition 97 (2013): 1044–1052.

[259] S. J. O'Keefe, J. V. Li, L. Lahti, et al., “Fat, Fibre and Cancer Risk in African Americans and Rural Africans,” Nature Communications 6 (2015): 6342.

[260] M. Park, J. Kwon, H. J. Shin, et al., “Butyrate Enhances the Efficacy of Radiotherapy via FOXO3A in Colorectal Cancer Patient‑Derived Organoids,” International Journal of Oncology 57 (2020): 1307–1318.

[261] A. J. Vargas, B. C. Wertheim, E. W. Gerner, et al., “Dietary Polyamine Intake and Risk of Colorectal Adenomatous Polyps,” American Journal of Clinical Nutrition 96 (2012): 133–141.

[262] A. J. Vargas, E. L. Ashbeck, B. C. Wertheim, et al., “Dietary Polyamine Intake and Colorectal Cancer Risk in Postmenopausal Women,” American Journal of Clinical Nutrition 102 (2015): 411–419.

[263] I. Subramanian, S. Verma, S. Kumar, et al., “Multi-omics Data Integration, Interpretation, and Its Application,” Bioinformatics and Biology Insights 14 (2020): 1177932219899051.

[264] W. Jin, J. M. Stokes, R. T. Eastman, et al., “Deep Learning Identifies Synergistic Drug Combinations for Treating COVID-19,” Proceedings of the National Academy of Sciences of the United States of America 118 (2021): e2105070118.

[265] A. I. Sigurdsson, I. Louloudis, K. Banasik, et al., “Deep Integrative Models for Large-scale human Genomics,” Nucleic Acids Research 51 (2023): e67.

[266] W. Zhu, L. Xie, J. Han, et al., “The Application of Deep Learning in Cancer Prognosis Prediction,” Cancers (Basel) 12 (2020): 603.

[267] O. B. Poirion, Z. Jing, K. Chaudhary, et al., “DeepProg: An Ensemble of Deep-learning and Machine-learning Models for Prognosis Prediction Using Multi-omics Data,” Genome Medicine 13 (2021): 112.

[268] C. Fernandez-Rozadilla, M. Timofeeva, Z. Chen, et al., “Deciphering Colorectal Cancer Genetics Through Multi-omic Analysis of 100,204 Cases and 154,587 Controls of European and East Asian Ancestries,” Nature Genetics 55 (2023): 89–99.

[269] T. T. Jayakrishnan, N. Sangwan, S. V. Barot, et al., “Multi-omics Machine Learning to Study Host-microbiome Interactions in Early-onset Colorectal Cancer,” Npj Precision Oncology 8 (2024): 146.

[270] S. N. Reinke, H. Gallart-Ayala, C. Gómez, et al., “Metabolomics Analysis Identifies Different Metabotypes of Asthma Severity,” European Respiratory Journal 49 (2017): 1601740.

[271] M. Wills-Karp and S. L. Ewart, “Time to Draw Breath: Asthma-susceptibility Genes Are Identified,” Nature Reviews Genetics 5 (2004): 376–387.

[272] J. Lipkova, R. J. Chen, B. Chen, et al., “Artificial Intelligence for Multimodal Data Integration in Oncology,” Cancer Cell 40 (2022): 1095–1110.

[273] A. Echle, N. T. Rindtorff, T. J. Brinker, et al., “Deep Learning in Cancer Pathology: A New Generation of Clinical Biomarkers,” British Journal of Cancer 124 (2021): 686–696.

[274] W. Barrios, B. Abdollahi, M. Goyal, et al., “Bladder Cancer Prognosis Using Deep Neural Networks and Histopathology Images,” Journal of Pathology Informatics 13 (2022): 100135.

[275] N. Coudray, P. S. Ocampo, T. Sakellaropoulos, et al., “Classification and Mutation Prediction From Non-small Cell Lung Cancer Histopathology Images Using Deep Learning,” Nature Medicine 24 (2018): 1559–1567.

[276] Y. Fu, A. W. Jung, R. V. Torne, et al., “Pan-cancer Computational Histopathology Reveals Mutations, Tumor Composition and Prognosis,” Nature Cancer 1 (2020): 800–810.

[277] N. Eliyatkın, E. Yalçın, B. Zengel, et al., “Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to a New Age, and a New Way,” European Journal of Breast Health 11 (2015): 59–66.

[278] Y. Sun, S. Zhu, K. Ma, et al., “Identification of 12 Cancer Types Through Genome Deep Learning,” Scientific Reports 9 (2019): 17256.

[279] P. Courtiol, C. Maussion, M. Moarii, et al., “Deep Learning-based Classification of Mesothelioma Improves Prediction of Patient Outcome,” Nature Medicine 25 (2019): 1519–1525.

[280] D. Capper, D. Stichel, F. Sahm, et al., “Practical Implementation of DNA Methylation and Copy-number-based CNS Tumor Diagnostics: The Heidelberg Experience,” Acta Neuropathologica 136 (2018): 181–210.

[281] S. Huang, J. Yang, N. Shen, et al., “Artificial Intelligence in Lung Cancer Diagnosis and Prognosis: Current Application and Future Perspective,” Seminars in Cancer Biology 89 (2023): 30–37.

[282] N. Erho, A. Crisan, I. A. Vergara, et al., “Discovery and Validation of a Prostate Cancer Genomic Classifier That Predicts Early Metastasis Following Radical Prostatectomy,” PLoS ONE 8 (2013): e66855.

[283] H. Shimizu and K. I. Nakayama, “A 23 Gene-based Molecular Prognostic Score Precisely Predicts Overall Survival of Breast Cancer Patients,” EBioMedicine 46 (2019): 150–159.

[284] O. J. Skrede, S. De Raedt, A. Kleppe, et al., “Deep Learning for Prediction of Colorectal Cancer Outcome: A Discovery and Validation Study,” Lancet 395 (2020): 350–360.

[285] P. Mobadersany, S. Yousefi, M. Amgad, et al., “Predicting Cancer Outcomes From Histology and Genomics Using Convolutional Networks,” Proceedings of the National Academy of Sciences of the United States of America 115 (2018): E2970–E2979.

[286] A. Ibrahim, A. Lashen, M. Toss, et al., “Assessment of Mitotic Activity in Breast Cancer: Revisited in the Digital Pathology Era,” Journal of Clinical Pathology 75 (2022): 365–372.

[287] J. Yu, X. Wu, J. Song, et al., “Loss of MHC-I Antigen Presentation Correlated With Immune Checkpoint Blockade Tolerance in MAPK Inhibitor-resistant Melanoma,” Frontiers in Pharmacology 13 (2022): 928226.

[288] L. A. Hildebrand, C. J. Pierce, M. Dennis, et al., “Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer,” Cancers (Basel) 13 (2021): 391.

[289] H. S. Muti, L. R. Heij, G. Keller, et al., “Development and Validation of Deep Learning Classifiers to Detect Epstein-Barr Virus and Microsatellite Instability Status in Gastric Cancer: A Retrospective Multicentre Cohort Study,” The Lancet Digital Health 3 (2021): e654–e664.

[290] R. Hong, W. Liu, D. DeLair, et al., “Predicting Endometrial Cancer Subtypes and Molecular Features From Histopathology Images Using Multi-resolution Deep Learning Models,” Cell Reports Medicine 2 (2021): 100400.

[291] H. Xu, Z. Liu, S. Weng, et al., “Artificial Intelligence-driven Consensus Gene Signatures for Improving Bladder Cancer Clinical Outcomes Identified by Multi-center Integration Analysis,” Molecular Oncology 16 (2022): 4023–4042.

[292] B. Weigelt, H. A. Vargas, P. Selenica, et al., “Radiogenomics Analysis of Intratumor Heterogeneity in a Patient with High-Grade Serous Ovarian Cancer,” JCO Precision Oncology 3 (2019).

[293] A. Jiménez-Sánchez, P. Cybulska, K. L. Mager, et al., “Unraveling Tumor-immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy,” Nature Genetics 52 (2020): 582–593.

[294] A. Kleppe, O. J. Skrede, S. De Raedt, et al., “Designing Deep Learning Studies in Cancer Diagnostics,” Nature Reviews Cancer 21 (2021): 199–211.

[295] K. M. Boehm, P. Khosravi, R. Vanguri, et al., “Harnessing Multimodal Data Integration to Advance Precision Oncology,” Nature Reviews Cancer 22 (2022): 114–126.

[296] Y. Zhu, T. Brettin, Y. A. Evrard, et al., “Ensemble Transfer Learning for the Prediction of Anti-cancer Drug Response,” Scientific Reports 10 (2020): 18040.

[297] Y. Qu, G. Yue, C. Shang, et al., “Multi-criterion Mammographic Risk Analysis Supported With Multi-label Fuzzy-rough Feature Selection,” Artificial Intelligence in Medicine 100 (2019): 101722.

[298] C. Zhu, S. Preissl, and B. Ren, “Single-cell Multimodal Omics: The Power of Many,” Nature Methods 17 (2020): 11–14.

[299] F. Wang, R. Kaushal, and D. Khullar, “Should Health Care Demand Interpretable Artificial Intelligence or Accept “Black Box” Medicine?,” Annals of Internal Medicine 172 (2020): 59–60.

[300] G. Novakovsky, N. Dexter, M. W. Libbrecht, et al., “Obtaining Genetics Insights From Deep Learning via Explainable Artificial Intelligence,” Nature Reviews Genetics 24 (2023): 125–137.

[301] X. Liu, L. Faes, M. J. Calvert, et al., “Extension of the CONSORT and SPIRIT Statements,” Lancet 394 (2019): 1225.

[302] M. Stoeckius, C. Hafemeister, W. Stephenson, et al., “Simultaneous Epitope and Transcriptome Measurement in Single Cells,” Nature Methods 14 (2017): 865–868.

[303] S. Pott, “Simultaneous Measurement of Chromatin Accessibility, DNA Methylation, and Nucleosome Phasing in Single Cells,” Elife 6 (2017): e23203.

[304] P. S. Reel, S. Reel, E. Pearson, et al., “Using Machine Learning Approaches for Multi-omics Data Analysis: A Review,” Biotechnology Advances 49 (2021): 107739.

[305] S. Z. Wu, G. Al-Eryani, D. L. Roden, et al., “A Single-cell and Spatially Resolved Atlas of human Breast Cancers,” Nature Genetics 53 (2021): 1334–1347.

[306] “Method of the Year 2020: Spatially Resolved Transcriptomics,” Nature Methods 18 (2021): 1.

[307] C. Bock, M. Boutros, J. G. Camp, et al., “The Organoid Cell Atlas,” Nature Biotechnology 39 (2021): 13–17.

[308] S. Mo, P. Tang, W. Luo, et al., “Patient-Derived Organoids From Colorectal Cancer With Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy,” Advanced Science (Weinheim) 9 (2022): e2204097.

[309] A. Yokoyama, N. Kakiuchi, T. Yoshizato, et al., “Age-related Remodelling of Oesophageal Epithelia by Mutated Cancer Drivers,” Nature 565 (2019): 312–317.

[310] K. Yizhak, F. Aguet, J. Kim, et al., “RNA Sequence Analysis Reveals Macroscopic Somatic Clonal Expansion Across Normal Tissues,” Science 364 (2019): eaaw0726.

[311] H. J. Snippert, L. G. van der Flier, T. Sato, et al., “Intestinal Crypt Homeostasis Results From Neutral Competition Between Symmetrically Dividing Lgr5 Stem Cells,” Cell 143 (2010): 134–144.

[312] B. Waclaw, I. Bozic, M. E. Pittman, et al., “A Spatial Model Predicts That Dispersal and Cell Turnover Limit Intratumour Heterogeneity,” Nature 525 (2015): 261–264.

[313] M. Vihinen, “Individual Genetic Heterogeneity,” Genes (Basel) 13 (2022): 1626.

[314] R. Stark, M. Grzelak, and J. Hadfield, “RNA Sequencing: The Teenage Years,” Nature Reviews Genetics 20 (2019): 631–656.

[315] R. J. Rotello and T. D. Veenstra, “Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics,” Current Protein & Peptide Science 22 (2021): 121–133.

[316] D. Chong, N. C. Jones, R. B. Schittenhelm, et al., “Multi-omics Integration and Epilepsy: Towards a Better Understanding of Biological Mechanisms,” Progress in Neurobiology 227 (2023): 102480.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.